NEW YORK— Diagnostics startup Plexision aims to cut down delays in testing for organ transplant rejection with an ant
Personalized Medicine For Better Health
31, Oct 2022
23, Oct 2022
Plexision, a biotechnology company, which provides personalized diagnostic testing services for organ transplant pati
23, Oct 2022
Plexision, a US-based biotechnology company, has initiated overseas operations with the establishment of a reference
23, Oct 2022
Plexision, a biotechnology company, is offering the first blood test panel capable of reporting the risk of cytomegal
28, Feb 2021
- On February 27, the FDA issued an Emergency Use Authorization for Johnson and Johnson’s non-mRNA vaccine.
13, Dec 2020
Results of Phase 2/3 Clinical Trial:
17, Oct 2020
WHO Solidarity Trial of Repurposed Antiviral Drugs in COVID-19 Reports Little to No Effect on Mortality, Seve
15, Nov 2016
Predicting cytomegalovirus viremia after liver or intestine transplantation (LTx, ITx) with CMV-specific T-cell subse
15, Nov 2016
Allospecific CD154+T-cytotoxic memory cells (CD154+TcM) predict acute cellular rejection after liver transplantation
About
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to
- - Assess disease risk for several immunological disorders.
- - Predict the success of a drug for a specific patient.
- - Develop dosing recommendations for new immunological drugs.
Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.
Contact
- +1 (855) 753-9474
- info@plexision.com
- 4424 Penn Ave., #202, Pittsburgh, PA 15224 USA